Citigroup’s Fractyl Health GUTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-35,076
Closed -$77.2K 6471
2025
Q4
$77.2K Buy
35,076
+34,859
+16,064% +$56.1K ﹤0.01% 4429
2025
Q3
$345 Buy
217
+3
+1% +$4 ﹤0.01% 5733
2025
Q2
$347 Sell
214
-23,800
-99% -$38.5K ﹤0.01% 5460
2025
Q1
$28.6K Sell
24,014
-2,879
-11% -$4.6K ﹤0.01% 5017
2024
Q4
$55.4K Buy
26,893
+2,199
+9% +$5.12K ﹤0.01% 5059
2024
Q3
$62.5K Buy
24,694
+23,041
+1,394% +$75.2K ﹤0.01% 4950
2024
Q2
$7.06K Sell
1,653
-46,077
-97% -$296K ﹤0.01% 5213
2024
Q1
$353K Buy
+47,730
New +$402K ﹤0.01% 3754

Other funds holding GUTS

Citigroup's GUTS Position: Q1 2026 in Review

Citigroup sold out of Fractyl Health (GUTS) in Q1 2026, closing a stake of 35,076 shares — an estimated $77.2K sold.

Citigroup first reported a position in GUTS in Q1 2024 and held it in 8 quarters. The position peaked at $353K in Q1 2024. 83 funds tracked by Wall St. Rank hold GUTS as of Q1 2026.

  • Citigroup reported no remaining Fractyl Health position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 35,076 Fractyl Health shares in Q1 2026, an estimated $77.2K.
  • Citigroup first reported a position in Fractyl Health in Q1 2024 and held it in 8 quarters.
  • Citigroup's Fractyl Health position peaked at $353K in Q1 2024.
  • 83 funds tracked by Wall St. Rank held Fractyl Health as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.